Kura Oncology, Inc. (KURA) P/E Ratio History
Insufficient DataInsufficient historical P/E data to classify valuation. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Kura Oncology, Inc. (KURA) trades at a price-to-earnings ratio of -3.1x, with a stock price of $9.93 and trailing twelve-month earnings per share of $-3.32.
Compared to the Healthcare sector median P/E of 22.1x, KURA trades at a 114% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, KURA trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our KURA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
KURA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
KURA P/E vs Peers
Oncology Therapeutics Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $203M | 4.1Lowest | 4.04Best | +49% | |
| $11B | 635.1 | - | -69% | |
| $7B | 10.2 | - | +264%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KURA — Frequently Asked Questions
Quick answers to the most common questions about buying KURA stock.
What is KURA's P/E ratio?
Kura Oncology, Inc. (KURA) trailing twelve-month P/E ratio is -3.1x, based on TTM diluted EPS of $-3.32. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is KURA stock overvalued or undervalued?
KURA current P/E: -3.1x. 5-year average P/E: N/A. Percentile: N/A.
Is KURA stock expensive?
KURA is fairly valued relative to its own history. The current P/E of -3.1x is near the 5-year average of N/A (N/A percentile of historical range).
What is KURA's historical P/E range?
Over the past 5 years, KURA's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of -3.1x places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does KURA's P/E compare to the S&P 500?
KURA trades at -3.1x P/E versus the S&P 500 median of 24.4x. The 113% discount to the market suggests lower growth expectations or perceived higher risk.
How does KURA's valuation compare to Healthcare peers?
Kura Oncology, Inc. P/E of -3.1x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is KURA's PEG ratio?
KURA PEG ratio is N/A, based on a P/E of -3.1x and EPS growth of -57.4%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is KURA's earnings yield?
KURA earnings yield is N/A, the inverse of its -3.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.